



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Selzentry™

**Common Name:** Maraviroc

**PDL Category:** Antiretrovirals

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
N/A	

#### Summary

**Indications and Usage:** Treatment of adults infected with only CCR5-tropic HIV-1

**Mechanism of Action:** Selectively binds to human chemokine receptor CCR5 on the cell membrane preventing the CCR5-tropic HIV-1 from entering cells.

**Dosage Forms:** Tablets; 150mg and 300mg

**Recommended Dosage:** 150mg – 600mg twice daily (dependant on other drugs in regimen that affect CYP3A)

**Common Adverse Drug Reactions:** Cough, pyrexia, URI, rash, abdominal pain, dizziness, hepatotoxicity

**Contraindications:** Previous hypersensitivity to any component of the product

**Manufacturer:** Pfizer, Inc.

**Analysis:** Selzentry™ received accelerated approval by the FDA as the first drug in a new class called CCR5 antagonists. As opposed to other available antiretrovirals, maraviroc fights the HIV virus on the outside of the surface of cells before it can enter, rather than attacking the virus from the inside out. Selzentry™ is to be used in combination with other antiretrovirals in patients who test positive for CCR5-tropic HIV-1. Special testing is required to confirm that this type of HIV virus is present prior to initiating therapy with Selzentry™. In early clinical trials, those who had maraviroc added to their antiretroviral regimen showed a mean decrease from baseline in HIV-1 RNA of 1.96 log<sub>10</sub> copies/mL compared to 0.99 log<sub>10</sub> copies/mL in the placebo group in 24 weeks. Maraviroc is not recommended to be used as first line therapy. It also represents a more costly choice than other anti-retrovirals. To begin with, the drug itself is more expensive than other alternatives in the class. However, the cost differential is compounded even more by the required laboratory testing, as well as the fact that it is recommended to be taken at high dosages in combination with certain other HIV medications. For these reasons, we recommend that Selzentry be added as a Non-Recommended Drug.

**IME Recommendation:**

- Preferred Drug
- Non-Preferred Drug
- Preferred Drug with Conditions
- Recommended Drug
- Non-Recommended Drug